PapersPMID:37767399
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.
- findings
- 5
- compound
- 1
- endpoints
- 5
- no difference found
- 4
What moved
How to read these marks →- Decreases LDL cholesterol
insufficientreplicated ×2
“Compared with model group, the resveratrol group manifested a significant reducing effect on LDL-C level [SMD = −2.01, 95% CI (−2.77, −1.25), p < 0.0001] (Supplementary Figure S3A A).”
- Study
- animal · not in humans
- Participants
- 208
- Effect
- −2.01 standardised mean difference, 95% CI −2.77 to −1.25
- Dose studied
- 20-400 mg/kg, 4-20 weeks, pooled across studies
- Population
- rodents with diet-induced NAFLD models, resveratrol vs model/control group, preclinical meta-analysis, 13 studies, 208 animals
What did not
“The result indicated that there was just the trend of decrease but no significance after treatment with resveratrol compared with placebo in BW [SMD = − 0.08, 95% CI (−0.35, 0.18), p = 0.544], BMI [SMD = − 0.07, 95% CI (−0.33, 0.20), p = 0.633], WC [SMD = −0.73, 95% CI (−1.97, 0.51), p = 0.249] and WHR [SMD = −0.12, 95% CI (−0.40, 0.16), p = 0.405] (Supplementary Figures S14, 15).”
- Study
- meta-analysis
- Effect
- −0.07 standardised mean difference, 95% CI −0.33 to 0.2
- Dose studied
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
- Study
- meta-analysis
- Effect
- −0.12 standardised mean difference, 95% CI −0.4 to 0.16
- Dose studied
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
“Interestingly, the result suggested that there was no significant efficacy of resveratrol on ALT level in NAFLD patients [SMD = −0.16, 95% CI (−0.67, 0.35), p = 0.542], nor was the efficacy in AST [SMD = −0.39, 95% CI (−0.95, 0.16), p = 0.167].”
- Study
- meta-analysis
- Effect
- −0.16 standardised mean difference, 95% CI −0.67 to 0.35
- Dose studied
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
- Study
- meta-analysis
- Effect
- −0.39 standardised mean difference, 95% CI −0.95 to 0.16
- Dose studied
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Study record
- Design
- meta-analysis
- Species
- mixed
- Population
- 27 preclinical rodent studies (Sprague-Dawley rats, C57BL/6 mice, Wistar rats, Obese Zucker rats) with NAFLD models (high-fat diet or methionine-choline-deficient diet), and 5 randomized controlled trials in adult patients diagnosed with nonalcoholic fatty liver disease (NAFLD)
- Participants
- 216
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 41
resveratrol